AbbVie's Humira was the world's best-selling drug for many years. Now it faces competition for copycats that cost a fraction of its price. David J. Phillip/AP hide caption
biosimilar biosimilar
Stories About
biosimilar
Humira, the injectable biologic treatment for rheumatoid arthritis, now faces its first competition from one of several copycat "biosimilar" drugs expected to come to market this year. Some patients spend $70,000 a year on Humira. JB Reed/Bloomberg via Getty Images hide caption
Susie Christoff tried several drugs to cope with her painful psoriatic arthritis before finding Cosentyx worked the best. The problem was the cost. Chris Bartlett/for Kaiser Health News hide caption
Why The U.S. Remains The Most Expensive Market For 'Biologic' Drugs In The World
A patient with Crohn's disease receives an IV infusion of Remicade, or infliximab. Dr P. Marazzi/Science Source hide caption